Long-Term Outcome of Bifurcation Stenting With Drug-Eluting Stents.

There are little long-term clinical data regarding the safety and efficacy of using 2 drug-eluting stents (DESs) to treat coronary bifurcation lesions. We obtained clinical follow-up for 124 consecutive patients who underwent bifurcation stenting with 2 DESs. Major adverse cardiac events (MACEs) were defined as cardiac death, acute myocardial infarction (AMI), and target vessel revas-cularization (TVR). Sixty-four (52%) patients underwent "crush," 42 (34%) patients underwent T stent, and 18 (14%) patients underwent kissing stent. Major adverse cardiac events were observed in 19 patients (17%) at 1 year: 6 (5%) AMI, 13 (12%) TVR, and no deaths, and 29 patients (26 %) at a mean follow-up of 22 months: 7 (6%) AMI, 21 (19%) TVR, and 1 (1%) death. No statistically significant risk factors for long-term MACEs were identified. It appears that treating bifurcation lesions with 2 DESs when necessary can be performed with an acceptable MACE rate. [ABSTRACT FROM AUTHOR]

Copyright of Angiology is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)